Compendia Bioscience

Company Management Team Careers Partners History

Products Oncomine Power Tools Edition Oncomine Concepts Edition Oncomine Research Edition Oncomine Gene Browser

Translational Medicine OncoPredictor Target Validation

News Press Releases Publications Posters Citations Events Webinars

08 OCT 2012
LIFE TECHNOLOGIES ACQUIRES COMPENDIA BIOSCIENCE

Life Technologies (NASDAQ: LIFE) today announced the acquisition of Compendia Bioscience, a preeminent cancer bioinformatics company widely used by the pharmaceutical industry to identify novel gene targets for drug discovery and development. Its deep oncology expertise and high-value, proprietary assets enhance Life's diagnostic development capabilities across multiple platforms, including next-generation sequencing, qPCR and proteome analysis.

27 JUL 2010
THREE INDEPENDENT STUDIES DEMONSTRATE ASSOCIATION OF 3q26 - 3q28 GENES WITH SQUAMOUS CELL CARCINOMAS.

Although the 3q26 - 3q28 chromosomal region contains many candidate oncogenes (e.g., TP63, PIK3CA, and DCUN1D1) the precise target of recurrent amplifications in this region had, until recently, been undetermined.

Please direct inquiries to Life Technologies.